Prophylactic treatments of neovascularisation in macular degeneration
CA 2336703 A1 · Owner: Billson, Francis Alfred · Inventors: Gillies, Mark Cedric; Penfold, Philip Leslie; Billson, Francis Alfred
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to the prophylaxis of choroidal neovascularisation in macular degeneration by the introduction of a suitable anti-inflammatory agent into the vitreous. In particular, it relates to the prophylaxis of neovascularisation with an anti-inflammatory steroid such as an 11-, substituted 16.alpha.17.alpha.-substituted methylenedioxy steroid of formula (I) wherein (a) is (b), (c), (d), (e), (f) (g), (h), (i), (j), (k) or (l); R1 , and R2 are hydrogen or alkyl; -Ca-Cb- is -CH2-CH2- -CH=CH-, (m) or (n); R3 is , methyl, hydroxymethyl or alkylcarbonyloxymethyl methylaminoalkylenecarbonyloxymethyl, or phenylaminoalkylenecarbonyloxymethyl; R4 is alkanoyl; and X is halogen in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 12, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 12, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 12, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.